All In Biotech

NDA 020742 · Alcon

Bss

Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Citrate · Irrigation

Last checked: Nov 20, 2026Latest source record: Nov 6, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 10, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

1,293

1,129 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 25, 2024.

INDICATIONS AND USAGE For use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 10, 1997 Original approval · Type 4 - New Combination
1 products under this application
  • BSS · CALCIUM CHLORIDE 0.48MG/ML; MAGNESIUM CHLORIDE 0.3MG/ML; POTASSIUM CHLORIDE 0.75MG/ML; SODIUM ACETATE 3.9MG/ML; SODIUM CHLORIDE 6.4MG/ML; SODIUM CITRATE 1.7MG/ML · SOLUTION, IRRIGATION · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxic anterior segment syndrome509
  • endophthalmitis313
  • hypopyon109
  • eye inflammation100
  • corneal oedema99
  • off label use86
  • post procedural complication79
  • vision blurred74
  • eye pain70
  • anterior chamber cell63
  • visual acuity reduced55
  • visual impairment54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
20053
200679
200736
200846
200936
201024
201137
2012104
201383
201469
201588
2016132
2017116
201866
201936
202017
202158
202289
202335
202436
202551
202630

Recalls

2 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bss (Balanced Salt Irrig Soln No.2)

2024 spending

$3K

Beneficiaries

41

126 claims

Per beneficiary

$82

$0.61 per unit

View as table
YearSpending
2020$4,792
2021$13,232
2022$10,120
2023$6,621
2024$3,362

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,408 on PubMed

Sponsor: Alcon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.